CoChat
Sign Up
Cited by 670Acute Ischemic Stroke ManagementAcute Myocardial Infarction ResearchIntracerebral and Subarachnoid Hemorrhage Research

The DOI matches its Crossref record; 465 of the 465 references it cites were found in a registry or an index.

Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association

Demaerschalk, Bart M., Kleindorfer, Dawn O., Adeoye, Opeolu M., Demchuk, Andrew M., Fugate, Jennifer E., Grotta, James C., Khalessi, Alexander A., Levy, Elad I., Palesch, Yuko Y., Prabhakaran, Shyam, Saposnik, Gustavo, Saver, Jeffrey L., Smith, Eric E.·2016·Stroke
DOI 10.1161/str.0000000000000086
Open this paper in CoChat — free account

Abstract

PURPOSE: To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant tissue-type plasminogen activator (alteplase) treatment in acute ischemic stroke. This will allow us to better inform stroke providers of quantitative and qualitative risks associated with alteplase administration under selected commonly and uncommonly encountered clinical circumstances and to identify future research priorities concerning these eligibility criteria, which could potentially expand the safe and judicious use of alteplase and improve outcomes after stroke. METHODS: Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association Stroke Council's Scientific Statement Oversight Committee and the American Heart Association's Manuscript Oversight Committee. The writers used systematic literature reviews, references to published clinical and epidemiology studies, morbidity and mortality reports, clinical and public health guidelines, authoritative statements, personal files, and expert opinion to summarize existing evidence and to indicate gaps in current knowledge and, when appropriate, formulated recommendations using standard American Heart Association criteria. All members of the writing group had the opportunity to comment on and approved the final version of this document. The document underwent extensive American Heart Association internal peer review, Stroke Council Leadership review, and Scientific Statements Oversight Committee review before consideration and approval by the American Heart Association Science Advisory and Coordinating Committee. RESULTS: After a review of the current literature, it was clearly evident that the levels of evidence supporting individual exclusion criteria for intravenous alteplase vary widely. Several exclusionary criteria have already undergone extensive scientific study such as the clear benefit of alteplase treatment in elderly stroke patients, those with severe stroke, those with diabetes mellitus and hyperglycemia, and those with minor early ischemic changes evident on computed tomography. Some exclusions such as recent intracranial surgery are likely based on common sense and sound judgment and are unlikely to ever be subjected to a randomized, clinical trial to evaluate safety. Most other contraindications or warnings range somewhere in between. However, the differential impact of each exclusion criterion varies not only with the evidence base behind it but also with the frequency of the exclusion within the stroke population, the probability of coexistence of multiple exclusion factors in a single patient, and the variation in practice among treating clinicians.

Overview

Integrity signals

Registry

Crossref · 10.1161/str.0000000000000086

Cites

465 of 465 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 13

  1. 10.1001/jama.1995.03530130023023 · DOI
  2. 10.1161/str.28.11.2119 · DOI
  3. Ganesan V, Chong K, Evans J, Gordon A, Gumley D, Irwin P, Kirkham F, Lees J, O’Kelly D, Pountney T, Redahan E, Rideout S, Thompson D, Ward B, Wayne S, Williams A, Wood K, Anie K, Oni L. Pediatric Stroke Working Group. Stroke in Childhood: Clinical Guidelines for Diagnosis, Management, and Rehabilitation. London, UK: Royal College of Physicians; 2004.
  4. 10.1267/THRO06020362 · DOI
  5. 10.1161/str.28.11.2109 · DOI
  6. 10.1159/000334662 · DOI
  7. Antman EM Anbe DT Armstrong PW Bates ER Green LA Hand M Hochman JS Krumholz HM Kushner FG Lamas GA Mullany CJ Ornato JP Pearle DL Sloan MA Smith SC Jr. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction) (published corrections appear in Circulation. 2005;111:2013–2014. doi: 10.1161/01.CIR.0000163471.93598.4A Circulation. 2007;115:e411. doi:10.1161/CIRCULATIONAHA.107.183508 and Circulation. 2010;121:e441. doi: 10.1161/CIRCULATIONAHA.107.185624). Circulation. 2004;110:e82–e293. · DOI
  8. 10.1097/01.CCM.0000025211.61411.59 · DOI
  9. 10.1016/S0196064403004438 · DOI
  10. ACTIVASE® (alteplase) [package insert]. http://www.gene.com/download/pdf/activase_prescribing.pdf. Accessed October 8, 2015.
  11. Diabetic Retinopathy, Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 1993.
  12. 10.1161/01.STR.0000030108.47462 · DOI
  13. Gensicke H Seiffge DJ Polasek AE Peters N Bonati LH Lyrer PA Engelter ST. Long-term outcome in stroke patients treated with IV thrombolysis. Neurology. 2013;80:919–925. doi: 10.1212/WNL.0b013e3182840c35. · DOI

Cited by

Sorted by citations

See all 670

Related

See all

Metadata

Authors
Demaerschalk, B. M., Kleindorfer, D. O., Adeoye, O. M., Demchuk, A. M., Fugate, J. E., Grotta, J. C., Khalessi, A. A., Levy, E. I., Palesch, Y. Y., Prabhakaran, S., Saposnik, G., Saver, J. L., & Smith, E. E.
ORCID
Venue
Stroke
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2016-02
Volume
47
Issue
2
Pages
581-641
ISSN
  • 0039-2499 (ISSN-L)
  • 1524-4628
DOI
10.1161/str.0000000000000086
OpenAlex
W2203834727
Cited by
670
References
465
Citations by year
2026: 35 · 2025: 39 · 2024: 58 · 2023: 47 · 2022: 60 · 2021: 64 · 2020: 61 · 2019: 72 · 2018: 99 · 2017: 106 · 2016: 26
FWCI
60.37
Type
journal article
Language
en
Update notices
correction (2016-11-01)
Open access
closed
Locations
  • Stroke (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
Keywords
alteplase, intravenous thrombolysis, acute ischemic stroke, inclusion criteria, exclusion criteria, contraindications, tissue plasminogen activator, elderly stroke patients, severe stroke, diabetes mellitus, hyperglycemia, treatment safety
MeSH terms
Adult, Age Factors, Aged, Aged, 80 and over, American Heart Association, Brain Ischemia, Fibrinolytic Agents, Hemorrhage, Humans, Middle Aged, Tissue Plasminogen Activator, Societies, Medical, United States, Practice Guidelines as Topic, Risk Assessment, Patient Selection, Evidence-Based Medicine, Stroke, Administration, Intravenous

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review